BeiGene Ltd (BGNE)
167.53
+0.14
(+0.08%)
USD |
NASDAQ |
May 22, 16:00
167.53
0.00 (0.00%)
After-Hours: 20:00
BeiGene Cash from Operations (Quarterly): -308.57M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -308.57M |
| December 31, 2023 | -221.64M |
| September 30, 2023 | -78.15M |
| June 30, 2023 | -293.89M |
| March 31, 2023 | -563.78M |
| December 31, 2022 | -318.19M |
| September 30, 2022 | -561.91M |
| June 30, 2022 | -379.96M |
| March 31, 2022 | -236.56M |
| December 31, 2021 | -507.84M |
| September 30, 2021 | -495.71M |
| June 30, 2021 | -420.27M |
| March 31, 2021 | 125.10M |
| December 31, 2020 | -332.33M |
| September 30, 2020 | -346.24M |
| June 30, 2020 | -262.94M |
| March 31, 2020 | -341.94M |
| December 31, 2019 | -267.18M |
| September 30, 2019 | -265.01M |
| Date | Value |
|---|---|
| June 30, 2019 | -46.10M |
| March 31, 2019 | -171.98M |
| December 31, 2018 | -193.89M |
| September 30, 2018 | -132.18M |
| June 30, 2018 | -117.14M |
| March 31, 2018 | -104.50M |
| December 31, 2017 | 93.75M |
| September 30, 2017 | 6.60M |
| June 30, 2017 | -51.89M |
| March 31, 2017 | -35.71M |
| December 31, 2016 | -26.14M |
| September 30, 2016 | -24.28M |
| June 30, 2016 | -19.26M |
| March 31, 2016 | -19.84M |
| December 31, 2015 | -16.76M |
| September 30, 2015 | -9.879M |
| June 30, 2015 | -9.491M |
| March 31, 2015 | -3.711M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-563.78M
Minimum
Mar 2023
125.10M
Maximum
Mar 2021
-306.16M
Average
-313.38M
Median
Cash from Operations (Quarterly) Benchmarks
| Theravance Biopharma Inc | -1.022M |
| LumiraDx Ltd | -27.02M |
| Dr Reddy's Laboratories Ltd | 141.52M |
| ASLAN Pharmaceuticals Ltd | -- |
| Jazz Pharmaceuticals PLC | 267.23M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -209.83M |
| Cash from Financing (Quarterly) | 162.29M |
| Free Cash Flow | -1.566B |
| Free Cash Flow Per Share (Quarterly) | -4.811 |
| Free Cash Flow to Equity (Quarterly) | -641.63M |
| Free Cash Flow to Firm (Quarterly) | -501.62M |
| Free Cash Flow Yield | -8.90% |